Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.
作者信息
Polat Meltem, Yüksel Selçuk, Şahin Nuriye Ünal
机构信息
a Pamukkale University School of Medicine , Department of Pediatric Infectious Diseases , Denizli , Turkey.
b Pamukkale University School of Medicine , Department of Pediatric Rheumatology , Denizli , Turkey.
出版信息
Hum Vaccin Immunother. 2018;14(11):2802. doi: 10.1080/21645515.2018.1486157. Epub 2018 Jun 29.
Abstract
摘要
相似文献
1
Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.在接受依库珠单抗治疗的接种疫苗儿童中，因Y群脑膜炎奈瑟菌导致的致命性脑膜炎球菌血症。
Hum Vaccin Immunother. 2018;14(11):2802. doi: 10.1080/21645515.2018.1486157. Epub 2018 Jun 29.
2
Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.在接受依库珠单抗治疗的非典型溶血尿毒综合征婴儿中使用预防性阿莫西林预防脑膜炎球菌感染：两例报告
CEN Case Rep. 2020 Aug;9(3):247-251. doi: 10.1007/s13730-020-00465-x. Epub 2020 Apr 2.
3
Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.依库珠单抗治疗非典型溶血尿毒综合征患者中首剂脑膜炎球菌疫苗接种失败。
Nephrol Dial Transplant. 2020 Feb 1;35(2):298-303. doi: 10.1093/ndt/gfy225.
4
Meningococcemia in a vaccinated child receiving eculizumab and review of the literature.接种疫苗的儿童患脑膜炎球菌血症，并用依库珠单抗治疗：文献复习
Turk J Pediatr. 2023;65(1):129-134. doi: 10.24953/turkjped.2022.190.
5
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.在美国接受依库珠单抗治疗的商业保险人群的特征和脑膜炎奈瑟菌病预防策略。
PLoS One. 2020 Nov 12;15(11):e0241989. doi: 10.1371/journal.pone.0241989. eCollection 2020.
6
Meningococcemia in vaccinated patient under treatment with eculizumab.接受依库珠单抗治疗的接种疫苗患者发生的脑膜炎球菌血症。
Enferm Infecc Microbiol Clin. 2017 Mar;35(3):200-201. doi: 10.1016/j.eimc.2016.02.015. Epub 2016 Mar 16.
7
Post-eculizumab meningococcaemia in vaccinated patients.接种疫苗患者中的依库珠单抗治疗后脑膜炎球菌血症
Clin Microbiol Infect. 2018 Jan;24(1):89-90. doi: 10.1016/j.cmi.2017.07.011. Epub 2017 Jul 20.
8
9
Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab.长期使用依库珠单抗的年轻成人中，耐青霉素菌株导致B型脑膜炎球菌疫苗接种失败
Pediatrics. 2017 Sep;140(3). doi: 10.1542/peds.2016-2452. Epub 2017 Aug 11.
10
[Invasive meningococcal disease due to Neisseria meningitidis serogroup Y].由脑膜炎奈瑟菌Y群引起的侵袭性脑膜炎球菌病
Enferm Infecc Microbiol Clin. 2011 Aug-Sep;29(7):555-6. doi: 10.1016/j.eimc.2011.01.017. Epub 2011 Apr 19.
引用本文的文献
1
Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.接受依库珠单抗治疗的非典型溶血性尿毒症综合征患儿的脑膜炎球菌携带情况。
Children (Basel). 2024 Sep 25;11(10):1164. doi: 10.3390/children11101164.
2
Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study.脑膜炎球菌 A、C、W、Y 结合疫苗在原发性或继发性免疫缺陷青少年中的免疫原性：一项前瞻性观察性队列研究。
Pediatr Rheumatol Online J. 2023 Jul 20;21(1):73. doi: 10.1186/s12969-023-00846-3.
3
Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.利用日本药品不良事件报告数据库对日本依库珠单抗相关脑膜炎球菌病进行风险分析
Drug Healthc Patient Saf. 2020 Nov 10;12:207-215. doi: 10.2147/DHPS.S257009. eCollection 2020.
4
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.在美国接受依库珠单抗治疗的商业保险人群的特征和脑膜炎奈瑟菌病预防策略。
PLoS One. 2020 Nov 12;15(11):e0241989. doi: 10.1371/journal.pone.0241989. eCollection 2020.
5
Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.在接种含有因子 H 结合蛋白的脑膜炎 B 型疫苗的年轻成年人中抗因子 H 抗体反应性。
mSphere. 2019 Jul 3;4(4):e00393-19. doi: 10.1128/mSphere.00393-19.
6
Reply letter to "Fatal meningococcemia due to serogroup Y in a vaccinated child receiving eculizumab".致《接受依库珠单抗治疗的接种疫苗儿童发生Y群致死性脑膜炎球菌血症》的回复信
Hum Vaccin Immunother. 2018;14(11):2803-2804. doi: 10.1080/21645515.2018.1491247. Epub 2018 Jul 16.
本文引用的文献
1
Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.迈向全球控制脑膜炎奈瑟菌的进展：21 世纪的疫苗、当前指南以及未来疫苗开发的挑战。
Hum Vaccin Immunother. 2018 May 4;14(5):1146-1160. doi: 10.1080/21645515.2018.1451810. Epub 2018 May 9.
2
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.尽管接受了脑膜炎球菌疫苗，但接受依库珠单抗（Soliris）治疗的患者仍有患侵袭性脑膜炎球菌病的高风险。
MMWR Morb Mortal Wkly Rep. 2017 Jul 14;66(27):734-737. doi: 10.15585/mmwr.mm6627e1.
3
First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.非典型溶血性尿毒症综合征的一线、早期和长期依库珠单抗治疗：儿科患者病例系列
Paediatr Drugs. 2016 Dec;18(6):413-420. doi: 10.1007/s40272-016-0194-0.
Zotero 插件